Healthcare Industry News: Transdermal
News Release - November 1, 2007
Valeritas Announces Brand Name V-Go(TM) for Disposable Insulin Delivery DeviceSimple-to-Use V-Go(TM) Utilizes the Valeritas h-Patch(TM) Technology
PARSIPPANY, N.J., Nov. 1 (HSMN NewsFeed) -- Valeritas, LLC, a medical technology company committed to the development and commercialization of innovative drug delivery solutions, formally announced V-Go(TM) as the brand name of the Company's lead product, a disposable insulin delivery device which utilizes the h-Patch(TM) technology platform for continuous insulin delivery both at a set basal rate and for on-demand bolus dosing at mealtimes.
"We are excited to introduce V-Go(TM) as the name for our lead product, and are working to make it available for patients with diabetes in the coming year," said Tara Charvat, Vice President, Marketing and Marketing Operations of Valeritas. "V-Go(TM) was designed to mimic the physiologic distribution of insulin in a simple fashion, and we believe it has the potential to create a new standard for insulin delivery and improve patient care."
V-Go(TM) is a simple-to-use, once-daily, disposable insulin delivery device that provides a continuous set basal rate and on-demand bolus dosing for mealtime coverage via a rapid acting insulin analog. V-Go(TM) will enable the millions suffering from Type 2 diabetes to discreetly and conveniently deliver insulin throughout the day and on-demand dosing around mealtimes. Developed to help enhance a patient's glycemic control and improve compliance, V-Go(TM) is the smallest known FDA-cleared insulin delivery device with basal- bolus capability and no visible needle. The V-Go(TM) has received FDA 510(k) clearance and Phase IV clinical trials are in development to support broad marketing and reimbursement claims.
"Type 2 diabetes is a significant health problem for millions of people in the United States, and V-Go(TM) could provide many of these patients with an innovative, simple-to-use option for their insulin delivery needs," said Robert Gonnelli, President and CEO of Valeritas. "The development of V-Go(TM) reinforces our continued commitment to developing therapies that leverage unique drug delivery systems to provide patients with optimum care."
About Valeritas, LLC
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that directly improve clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch(TM) technology. The first use of the h-Patch(TM) technology is the V-Go(TM) disposable insulin delivery device. In addition to V-Go(TM) for the delivery of insulin, Valeritas' delivery technology portfolio includes the h-Patch(TM) for the delivery of other compounds beyond insulin, the e-Patch(TM) Controlled Release Disposable Micro Pump System, the Mini-Ject(TM) Pre-Filled Needle-Free Delivery System and the Micro-Trans(TM) Microneedle Transdermal Delivery Patch. These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.
Headquartered in Parsippany, N.J., Valeritas operates its R&D and clinical manufacturing in a state-of-the-art manufacturing and R&D facility in Shrewsbury, Massachusetts.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.